{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:54Z","timestamp":1793064414403,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.radonc.2025.110845","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:52:13Z","timestamp":1741913533000},"page":"110845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac"],"prefix":"10.1016","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-5713","authenticated-orcid":false,"given":"T.A.","family":"Lalmahomed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Willigenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.G.","family":"van de Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.N.","family":"de Groot-van Breugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.W.","family":"Snoeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Verkooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.N.","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.radonc.2025.110845_b0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2007.10.034","article-title":"MRI\/linac integration","volume":"86","author":"Lagendijk","year":"2008","journal-title":"Radiotherapy and Oncology."},{"key":"10.1016\/j.radonc.2025.110845_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1117874","article-title":"MRI-LINAC: A transformative technology in radiation oncology","author":"Ng","year":"2023","journal-title":"Front Oncol [Internet]."},{"key":"10.1016\/j.radonc.2025.110845_b0015","doi-asserted-by":"crossref","unstructured":"Westley RL, Biscombe K, Dunlop A, Mitchell A, Oelfke U, Nill S, et al. Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys [Internet]. 2024 Mar 1 [cited 2024 May 17];118(3):682\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37776979\/.","DOI":"10.1016\/j.ijrobp.2023.09.032"},{"key":"10.1016\/j.radonc.2025.110845_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial","author":"Ong","year":"2023","journal-title":"Radiother Oncol [Internet]."},{"key":"10.1016\/j.radonc.2025.110845_b0025","doi-asserted-by":"crossref","unstructured":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol [Internet]. 2022 Oct 1 [cited 2024 Jun 12];23(10):1308\u201320. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36113498\/.","DOI":"10.1016\/S1470-2045(22)00517-4"},{"key":"10.1016\/j.radonc.2025.110845_b0030","doi-asserted-by":"crossref","unstructured":"Willigenburg T, Zachiu C, Bol GH, de Groot-van Beugel EN, Lagendijk JJW, van der Voort van Zyp JRN, et al. Clinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion. Radiother Oncol [Internet]. 2022 Nov 1 [cited 2024 May 17];176:25\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36113777\/.","DOI":"10.1016\/j.radonc.2022.09.004"},{"key":"10.1016\/j.radonc.2025.110845_b0035","doi-asserted-by":"crossref","unstructured":"Tsekas G, Zachiu C, Bol GH, van der Voort van Zyp JRN, van de Pol SMG, de Boer JCJ, et al. Dose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system. Phys Imaging Radiat Oncol [Internet]. 2025 Jan 1 [cited 2025 Feb 18];33:100706. Available from: http:\/\/www.phiro.science\/article\/S2405631625000119\/fulltext.","DOI":"10.1016\/j.phro.2025.100706"},{"issue":"3","key":"10.1016\/j.radonc.2025.110845_b0040","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study\u2014An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy","volume":"13","author":"Teunissen","year":"2023","journal-title":"Pract Radiat Oncol."},{"key":"10.1016\/j.radonc.2025.110845_b0045","doi-asserted-by":"crossref","unstructured":"Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Int J Radiat Oncol Biol Phys [Internet]. 2019 Dec 1 [cited 2024 Jun 12];105(5):1086\u201394. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31419510\/.","DOI":"10.1016\/j.ijrobp.2019.08.007"},{"key":"10.1016\/j.radonc.2025.110845_b0050","doi-asserted-by":"crossref","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol [Internet]. 2019 Nov 1 [cited 2024 Jun 12];20(11):1531\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31540791\/.","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"10.1016\/j.radonc.2025.110845_b0055","doi-asserted-by":"crossref","unstructured":"Teunissen FR, Willigenburg T, Meijer RP, van Melick HHE, Verkooijen HM, van der Voort van Zyp JRN. The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating \u201ctrials within cohorts\u201d (TwiCs) for the evaluation of interventions for prostate cancer. World J Urol [Internet]. 2022 Sep 1 [cited 2024 May 17];40(9):2205\u201312. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35861861\/.","DOI":"10.1007\/s00345-022-04092-2"},{"key":"10.1016\/j.radonc.2025.110845_b0060","doi-asserted-by":"crossref","unstructured":"Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology [Internet]. 2000 [cited 2024 May 17];56(6):899\u2013905. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11113727\/.","DOI":"10.1016\/S0090-4295(00)00858-X"},{"key":"10.1016\/j.radonc.2025.110845_b0065","doi-asserted-by":"crossref","unstructured":"Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? 2011 [cited 2024 Jul 25]; Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpr.329.","DOI":"10.1002\/mpr.329"},{"key":"10.1016\/j.radonc.2025.110845_b0070","doi-asserted-by":"crossref","unstructured":"Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology [Internet]. 2015 Jan 1 [cited 2024 May 17];85(1):101\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25530370\/.","DOI":"10.1016\/j.urology.2014.08.044"},{"key":"10.1016\/j.radonc.2025.110845_b0075","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible Summary Tables with the gtsummary Package."},{"key":"10.1016\/j.radonc.2025.110845_b0080","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw [Internet]. 2011 Dec 12 [cited 2024 Jul 25];45(3):1\u201367. Available from: https:\/\/www.jstatsoft.org\/index.php\/jss\/article\/view\/v045i03."},{"key":"10.1016\/j.radonc.2025.110845_b0085","unstructured":"Pishgar F, Greifer N, Leyrat C, Stuart E. MatchThem:: Matching and Weighting after Multiple Imputation."},{"key":"10.1016\/j.radonc.2025.110845_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.05.028","article-title":"Patient-Reported Outcomes Following Magnetic Resonance-Guided Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis","author":"Westerhoff","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys [Internet]."},{"key":"10.1016\/j.radonc.2025.110845_b0095","doi-asserted-by":"crossref","unstructured":"Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, et al. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol [Internet]. 2023 Mar 16 [cited 2024 May 21];9(3):365\u201373. Available from: https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2800541.","DOI":"10.1001\/jamaoncol.2022.6558"},{"issue":"46","key":"10.1016\/j.radonc.2025.110845_b0100","article-title":"Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer \u2013 Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial","volume":"1","author":"Fink","year":"2024","journal-title":"Clin Transl Radiat Oncol."},{"key":"10.1016\/j.radonc.2025.110845_b0105","doi-asserted-by":"crossref","unstructured":"Tetar SU, Bruynzeel AME, Oei SS, Senan S, Fraikin T, Slotman BJ, et al. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur Urol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 11];4(4):628\u201334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32536573\/.","DOI":"10.1016\/j.euo.2020.05.007"},{"key":"10.1016\/j.radonc.2025.110845_b0110","doi-asserted-by":"crossref","unstructured":"Willigenburg T, van der Velden JM, Zachiu C, Teunissen FR, Lagendijk JJW, Raaymakers BW, et al. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy. Radiotherapy and Oncology [Internet]. 2022 Jun 1 [cited 2024 May 21];171:182\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35489444\/.","DOI":"10.1016\/j.radonc.2022.04.022"},{"key":"10.1016\/j.radonc.2025.110845_b0115","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. 2017 [cited 2024 May 21]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"2","key":"10.1016\/j.radonc.2025.110845_b0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.prro.2023.08.017","article-title":"Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review","volume":"14","author":"Shimomura","year":"2024","journal-title":"Pract Radiat Oncol."},{"key":"10.1016\/j.radonc.2025.110845_b0125","article-title":"[cited 2024 May 21];34:92\u2013106","author":"Fast","year":"2024","journal-title":"Available from:"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T16:18:26Z","timestamp":1748017106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"alternative-id":["S0167814025001409"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110845","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110845"}}